Christopher C Griffith
Overview
Explore the profile of Christopher C Griffith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
1100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Xing J, Griffith C
Cancer Cytopathol
. 2023 Apr;
131(11):672-676.
PMID: 37068112
No abstract available.
12.
Magliocca K, Kaka A, Barrow E, Studer M, Griffith C, Ernst J, et al.
ORL J Otorhinolaryngol Relat Spec
. 2022 Dec;
85(2):80-87.
PMID: 36538901
Objectives: The aim of the study was to investigate the association of surgical margin conditions, including positive specimen margins revised to negative relative to local recurrence, disease-free survival, and overall...
13.
VanderLaan P, Roy-Chowdhuri S, Griffith C, Weiss V, Booth C
J Am Soc Cytopathol
. 2022 Oct;
11(6):403-414.
PMID: 36184436
Ancillary and molecular testing of cytopathology specimens has emerged as a reliable and useful tool to provide diagnostic information and treatment-related biomarker status for the management of cancer patients. The...
14.
Nichols M, Alruwaii F, Chaaban M, Cheng Y, Griffith C
Head Neck Pathol
. 2022 Sep;
17(1):259-264.
PMID: 36169791
Background: Biphenotypic sinonasal sarcoma (BSS) is a low-grade, locally aggressive sarcoma unique to the sinonasal region. BSS is most common in middle aged patients and affects women more frequently than...
15.
Smile T, Reddy C, Matia B, Fleming C, Domb C, Geiger J, et al.
Anticancer Res
. 2022 Jul;
42(8):3845-3852.
PMID: 35896238
Background/aim: Definitive treatment for locally advanced head and neck squamous cell carcinoma (LAHNSCC) is often compromised in older adults due to concerns about potential treatment toxicity intolerance. We reviewed our...
16.
van Zante A, Flanagan M, Floyd A, Johnson D, Manucha V, McGrath C, et al.
J Am Soc Cytopathol
. 2022 Jul;
11(5):306-312.
PMID: 35850973
Introduction: High-risk human papillomavirus (HR-HPV) status is critical in the diagnosis of oropharyngeal squamous cell carcinoma, informing prognosis and choice of therapy. HR-HPV status additionally plays a key role in...
17.
Manucha V, Adeniran A, Asiry S, Hoda R, Johnson D, van Zante A, et al.
J Am Soc Cytopathol
. 2022 Jul;
11(5):295-305.
PMID: 35810109
Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma is increasing in incidence and is often first diagnosed on a cytology fine needle aspiration (FNA) specimen of metastatic nodal disease of the...
18.
Allen-Proctor M, Rahman M, Reddy C, Koyfman S, Chute D, Griffith C
Head Neck Pathol
. 2022 May;
16(4):963-968.
PMID: 35499641
Depth of invasion (DOI) was added to the staging criteria for carcinoma of the lip and oral cavity in the 8th edition of the American Joint Committee on Cancer Staging...
19.
Wu S, Chen B, Fleming C, Shah A, Griffith C, Domb C, et al.
Head Neck
. 2022 Jan;
44(4):851-861.
PMID: 35040516
Background: The prognostication of Epstein-Barr virus (EBV) and human papillomavirus (HPV) status in nasopharyngeal cancer (NPC) is unclear. Methods: This retrospective study analyzed NPC from 2000 to 2019. Results: Seventy-eight...
20.
Shu L, Wang D, Nannapaneni S, Sun Y, Griffith C, Wang X, et al.
Oral Oncol
. 2021 Oct;
122:105546.
PMID: 34700281
Objective: To test the potential ability of tipifarnib to impair proliferation and to enhance the activity of the EGFR inhibitor cetuximab in wild-type H-Ras HNSCC, which accounts for the majority...